Alector Inc (ALEC)
NASDAQ:ALEC
Want to see ALEC full AI Analyst Report?
ALEC Stock Chart & Stats
$2.55
-$0.09(-4.55%)
At close: 4:00 PM EST
$2.55
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$0.90 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)732.83K
Market Cap
$284.74M
Enterprise Value$251.86M
Total Cash (Recent Filing)$256.02M
Total Debt (Recent Filing)$36.23M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Apr 30, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding110,362,580
10 Day Avg. Volume770,627
30 Day Avg. Volume732,833
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue11.97
Enterprise Value/Gross Profit13.41
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$3.38Price Target Upside32.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$36.77M
Bulls Say, Bears Say
Bulls Say
Differentiated Antibody MechanismThe lead anti‑amyloid antibody retaining full effector function supports more efficient plaque clearance and differentiates the program from competitors on potential efficacy grounds.
Funding For Clinical AdvancementSecured funding to advance two platform‑derived assets into clinical testing supports progression of the pipeline toward tangible clinical readouts.
Platform Pivot And StrategyA shift to a proprietary blood‑brain‑barrier platform and concentration on an anti‑amyloid antibody plus a tau siRNA program may concentrate value and clarify the development strategy.
Bears Say
Analyst Caution And Limited CatalystsAnalyst recommendations remain cautious because the pipeline offers limited catalysts for valuation re‑rating, which may restrict upside absent clear clinical validation.
Binary Risk From Interim Futility ReadoutAn interim futility analysis in the Phase 2 Alzheimer's study represents a binary clinical readout that could drive significant stock volatility if results are unfavorable.
Recent Late‑stage Trial FailureDiscontinuation of a late‑stage therapy following trial failure undermines confidence in the near‑term pipeline and raises questions about program reliability.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.90 and its highest was $3.40 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $284.74M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Apr 30, 2026 which is in 13 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Feb 25, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $0.034.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.28.
How many shares outstanding does Alector Inc have?
Alector Inc has 110,362,580 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went up 7.113%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.38 (32.55% Upside)
$3.38 (32.55% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 124.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
160.73%
12-Months-Change
Fundamentals
Return on Equity
-224.96%
Trailing 12-Months
Asset Growth
-37.38%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Stock 12 Month Forecast
Average Price Target
$3.38
▲(32.55% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---